Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

References

• WestermeyerJComorbid schizophrenia and substance abuse: a review of epidemiology and courseAm J Addict20061534535516966190
   PubMed Web of Science ®Google Scholar
• GreenAITohenMFHamerRMHGDH Research GroupFirst episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidolSchizophr Res20046612513515061244
   PubMed Web of Science ®Google Scholar
• SwoffordCDKasckowJWScheller-GilkeyGInderbitzinLBSubstance use: a powerful predictor of relapse in schizophreniaSchizophr Res1996201451518794502
   PubMed Web of Science ®Google Scholar
• WilkJMarcusSCWestJSubstance abuse and the management of medication nonadherence in schizophreniaJ Nerv Ment Dis200619445445716772865
   PubMed Web of Science ®Google Scholar
• CastleDJGalletlyCADarkFThe 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disordersMed J Aust201720650150528918734
   PubMed Web of Science ®Google Scholar
• MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag Care Spec Pharm20152175476826308223
   PubMed Web of Science ®Google Scholar
• KishiTOyaKIwataNLong-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trialsPsychiatry Res201624675075527863801
   PubMed Web of Science ®Google Scholar
• CitromeLKamatSASapinCCost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United StatesJ Med Econ20141756757624758296
   PubMedGoogle Scholar
• NaberDHansenKForrayCQualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophreniaSchizophr Res201516849850426232241
   PubMed Web of Science ®Google Scholar
• TempestMSapinCTelevantouFBeillatMTreurMPharmacoeconomic evaluation of aripiprazole once-monthly versus paliperidone palmitate in the UK: findings from QUALIFYValue Health201518A410A411
   Web of Science ®Google Scholar
• SapinCGimeno de la FuenteVBlancherPBeillatMCost effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate in SpainValue Health201518A410
   Web of Science ®Google Scholar
• SapinCHartryAKamatSABeillatMBakerRAEramoAPharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisDrugs Context2016521230127708677
   PubMedGoogle Scholar
  errata corrigeDrugs Context2017621250428706556
   PubMedGoogle Scholar
• PotkinSGLozeJYForrayCMultidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head-to-head trial of aripiprazole once-monthly and paliperidone palmitateInt J Neuropsychopharmacol201720404927927736
   PubMed Web of Science ®Google Scholar
• ThomasJECaballeroJHarringtonCAThe incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysisCurr Neuropharmacol20151368169126467415
   PubMed Web of Science ®Google Scholar
• KirinoESerum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychoticsAnn Gen Psychiatry2017164329209406
   PubMed Web of Science ®Google Scholar
• PotkinSGLozeJYForrayCReduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFYInt Clin Psychopharmacol20173214715428252452
   PubMed Web of Science ®Google Scholar
• PotkinSGLozeJYForrayCRelationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: a post-hoc analysis of the QUALIFY studyPLoS One201712e018347528837593
   PubMed Web of Science ®Google Scholar
  errata corrigePLoS One201712e018841629155881
   PubMedGoogle Scholar
• PaeCUWangSMHanCComparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparisonInt Clin Psychopharmacol20173223524828430670
   PubMed Web of Science ®Google Scholar
• CameronCZummoJDesaiDNDrakeCHuttonBKotbAWeidenPJAripiprazole lauroxil compared with paliperidone palmitate in patients with schizophrenia: an indirect treatment comparisonValue Health20172087688528712616
   PubMed Web of Science ®Google Scholar
• KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry20127361762422697189
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology2010352072208220555312
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry2011101221481243
   PubMed Web of Science ®Google Scholar
• TakahashiNTakahashiMSaitoTRandomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophreniaNeuropsychiatr Dis Treat201391889189824353421
   PubMed Web of Science ®Google Scholar
• MeltzerHYRisingerRNasrallahHAA randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophreniaJ Clin Psychiatry2015761085109026114240
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
   PubMed Web of Science ®Google Scholar
• MajerIMGaughranFSapinCBeillatMTreurMEfficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsJ Mark Access Health Policy2015327208
   PubMedGoogle Scholar
• FleischhackerWWSanchezRPerryPPAripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyBr J Psychiatry201420513514424925984
   PubMed Web of Science ®Google Scholar
• FleischhackerWWGopalSLaneRA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol20121510711821777507
   PubMed Web of Science ®Google Scholar
  errata corrigeInt J Neuropsychopharmacol201215119
   Google Scholar
• EmsleyRParelladaEBioqueMHerreraBHernandoTGarcía-DoradoMReal-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studiesInt Clin Psychopharmacol201833153328817397
   PubMed Web of Science ®Google Scholar
• DruaisSDoutriauxACognetMCost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in FrancePharmacoeconomics20163436339126883132
   PubMed Web of Science ®Google Scholar
• EinarsonTRPudasHGoswamiPvan ImpeKBerezaBGPharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in FinlandJ Med Econ20161911112026414966
   PubMed Web of Science ®Google Scholar
• TempestMSapinCBeillatMRobinsonPTreurMCost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UKJ Ment Health Policy Econ20151818520026729007
   PubMed Web of Science ®Google Scholar
• ZhuDZhangJWuJPaliperidone protects SH-SY5Y cells against MK-801-induced neuronal damage through inhibition of Ca2+ influx and regulation of SIRT1/miR-134 signal pathwayMol Neurobiol2016532498250926055227
   PubMed Web of Science ®Google Scholar
• PengLZhuDFengXPaliperidone protects prefrontal cortical neurons from damages caused by MK-801 via Akt1/GSK3β signaling pathwaySchizophr Res2013147142323583326
   PubMed Web of Science ®Google Scholar
• RoenkerNLGudelskyGAhlbrandREffect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801Neurosci Lett201150016717121699956
   PubMed Web of Science ®Google Scholar
• ZuccoliMLMuscellaAFucileCPaliperidone for the treatment of ketamine-induced psychosis: a case reportInt J Psychiatry Med20144810310825377151
   PubMed Web of Science ®Google Scholar
• IshiiDMatsuzawaDKanaharaNEffects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathwayNeurosci Lett2010471535720083164
   PubMed Web of Science ®Google Scholar
• DeianaSWatanabeAYamasakiYMK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiolBehav Pharmacol20152674876526287433
   PubMed Web of Science ®Google Scholar
• TuplinEWStoccoMRHolahanMRAttenuation of MK-801-induced behavioral perseveration by typical and atypical antipsychotic pretreatment in ratsBehav Neurosci201512939941126052791
   PubMed Web of Science ®Google Scholar
• NagaiTMuraiRMatsuiKAripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptorsPsychopharmacology (Berl)200920231532818679658
   PubMed Web of Science ®Google Scholar
• FeltensteinMWDoPHSeeRERepeated aripiprazole administration attenuates cocaine seeking in a rat model of relapsePsychopharmacology (Berl)200920740141119779699
   PubMed Web of Science ®Google Scholar
• MadhavanAArgilliEBonciAWhistlerJLLoss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental areaJ Neurosci201333123291233623884939
   PubMed Web of Science ®Google Scholar
• Oliveira-LimaAJMarinhoESantos-BaldaiaRContext-dependent efficacy of a counter-conditioning strategy with atypical neuroleptic drugs in mice previously sensitized to cocaineProg Neuropsychopharmacol Biol Psychiatry201773495527789219
   PubMed Web of Science ®Google Scholar
• WeeSWangZWoolvertonWLPulvirentiLKoobGFEffect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session durationNeuropsychopharmacology2007322238224717327886
   PubMed Web of Science ®Google Scholar
• OshibuchiHInadaKSugawaraHIshigookaJAripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized ratsEur J Pharmacol2009615839019477171
   PubMed Web of Science ®Google Scholar
• MavrikakiMNomikosGGPanagisGEfficacy of the atypical antipsychotic aripiprazole in D-amphetamine-based preclinical models of maniaInt J Neuropsychopharmacol20101354154820047715
   PubMed Web of Science ®Google Scholar
• BrownESJeffressJLigginJDGarzaMBeardLSwitching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazoleJ Clin Psychiatry20056675676015960570
   PubMed Web of Science ®Google Scholar
• BeresfordTPClappLMartinBWibergJLAlfersJBeresfordHFAripiprazole in schizophrenia with cocaine dependence: a pilot studyJ Clin Psychopharmacol20052536336616012280
   PubMed Web of Science ®Google Scholar
• BeresfordTBuchananJThummEBEmrickCWeitzenkampDRonanPJLate reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependenceJ Clin Psychopharmacol20173765766328984746
   PubMed Web of Science ®Google Scholar
• MeiniMMonciniMCecconiDSafety, tolerability, and self-rated effects of aripiprazole and ropinirole treatment for cocaine dependence: a pilot studyAm J Addict20112017918021314764
   PubMed Web of Science ®Google Scholar
• HaneyMRubinEFoltinRWAripiprazole maintenance increases smoked cocaine self-administration in humansPsychopharmacology (Berl)201121637938721373790
   PubMed Web of Science ®Google Scholar
• MoranLMPhillipsKAKowalczykWJAripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessmentBehav Pharmacol201728637327755017
   PubMed Web of Science ®Google Scholar
• KishiTMatsudaYIwataNCorrellCUAntipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trialsJ Clin Psychiatry201374e1169e118024434105
   PubMed Web of Science ®Google Scholar
• IndaveBIMinozziSPaniPPAmatoLAntipsychotic medications for cocaine dependenceCochrane Database Syst Rev20163CD00630626992929
   PubMed Web of Science ®Google Scholar
• MartinottiGDi NicolaMJaniriLEfficacy and safety of aripiprazole in alcohol dependenceAm J Drug Alcohol Abuse20073339340117613966
   PubMed Web of Science ®Google Scholar
• MartinottiGDi NicolaMDi GiannantonioMJaniriLAripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexoneJ Psychopharmacol20092312312918515460
   PubMed Web of Science ®Google Scholar
• TiihonenJKuoppasalmiKFöhrJA comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependenceAm J Psychiatry200716416016217202560
   PubMed Web of Science ®Google Scholar
• CoffinPOSantosGMDasMAripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trialAddiction201310875176123186131
   PubMed Web of Science ®Google Scholar
• SulaimanAHGillJSSaidMAZainalNZHusseinHMGuanNCA randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosisInt J Psychiatry Clin Pract20131713113822486597
   PubMed Web of Science ®Google Scholar
• FarniaVShakeriJTatariFRandomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosisAm J Drug Alcohol Abuse201440101524359506
   PubMed Web of Science ®Google Scholar
• WangGZhangYZhangSAripiprazole and risperidone for treatment of methamphetamine-associated psychosis in Chinese patientsJ Subst Abuse Treat201662848826733277
   PubMed Web of Science ®Google Scholar
• MontemitroCBaroniGCantelmiVLong-acting injectable aripiprazole as treatment for psychiatric patients comorbid with substance-related and addictive disorder: efficacy and safety. Abstract P.6.d.013 presented at the 30th ECNP Congress, Paris, France, 2–5 September, 2017Eur Neuropsychopharmacol201727Suppl 4S1072
   Google Scholar
• StarrHLBermakJMaoLRodriguezSAlphsLComparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: an exploratory analysis of the PRIDE studySchizophr Res2018194394628601497
   PubMed Web of Science ®Google Scholar
• LefebvrePMuserEJoshiKImpact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuseClin Ther2017391380.e41395.e428641996
   PubMed Web of Science ®Google Scholar
• JoshiKLafeuilleMHKamstraRReal-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefitsJ Comp Eff Res2018712113328809128
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology 028 CGI Clinical Global ImpressionsRockville, MDUS Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration1976217222
   Google Scholar
  (Italian version: Clinical Global Impressions (CGI)ContiL(versione italiana e adattamento a cura di): Repertorio delle scale di valutazione in psichiatriaFlorence, ItalySocietà Editrice Europea (SEE)1999215217
   Google Scholar
• LeonACShearMKKlermanGLPorteraLRosenbaumJFGoldenbergIA comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depressionJ Clin Psychopharmacol1993133273318227491
   PubMed Web of Science ®Google Scholar
• PinnaFDeriuLDianaECagliari Recovery Study GroupClinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disordersAnn Gen Psychiatry201514625699085
   PubMed Web of Science ®Google Scholar
• GlassmanAHJacksonWKWalshBTRooseSPRosenfeldBCigarette craving, smoking withdrawal, and clonidineScience19842268648666387913
   PubMed Web of Science ®Google Scholar
  Italian translation in:ManzatoENavaFCifelliGBiasinCGalvaninFL’assessment di I livello per la valutazione alcologica nella pratica clinica dei Servizi [First level assessment fo alcohologic evaluation in public clinical practice–Italian]Newsletter “Clinica dell’Alcolismo”20102 N°6, Mission 302752 ).
   Google Scholar
• WewersMERachfalCAhijevychKA psychometric evaluation of a visual analogue scale of craving for cigarettesWest J Nurs Res1990126726812238644
   PubMedGoogle Scholar
• HarperAon behalf of the WHOQOL groupWHOQOL-BREFIntroduction, Administration, Scoring and Generic Version of the Assessment Field Trial Version121996Geneva (CH)World Health Organization1996
   Google Scholar
  Italian validationDe GirolamoGRucciPScoccoPBecchiACoppaFD’AddarioADarúEDe LeoDGalassiLMangelliLMarsonCNeriGSoldaniLLa valutazione della qualità della vita: validazione del WHOQOL-Breve [Quality of life assessment: validation of the Italian version of the WHOQOL-Brief–Italian]Epidemiol Psichiatr Soc20009455510859875
   PubMedGoogle Scholar
• ShapiroSSWilkMBAnalysis of variance test for normality (complete samples)Biometrika196552591611
   Web of Science ®Google Scholar
• CohenJStatistical Power Analysis for the Behavioral SciencesNew YorkRoutledge1988
   Google Scholar
• SawilowskySNew effect size rules of thumbJ Mod Appl Stat Methods20098467474
   Google Scholar
• FeltensteinMWAltarCASeeREAripiprazole blocks reinstatement of cocaine seeking in an animal model of relapseBiol Psychiatry20076158259016806092
   PubMed Web of Science ®Google Scholar
• MizushimaJTakahataKKawashimaNKatoMSuccessful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drugAnn Gen Psychiatry2012111922769562
   PubMed Web of Science ®Google Scholar
• IsHakWWDavisMJeffreyJThe role of dopaminergic agents in improving quality of life in major depressive disorderCurr Psychiatry Rep20091150350819909674
   PubMed Web of Science ®Google Scholar
• SharotTShinerTBrownACFanJDolanRJDopamine enhances expectation of pleasure in humansCurr Biol2009192077208019913423
   PubMed Web of Science ®Google Scholar
• WeigmannKFeel the beat: music exploits our brain’s ability to predict and the dopamine-reward system to instil pleasureEMBO Rep20171835936228126726
   PubMed Web of Science ®Google Scholar
• CaravaggioFFervahaGBrowneCJGerretsenPRemingtonGGraff-GuerreroAReward motivation in humans and its relationship to dopamine D2/3 receptor availability: a pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imagingJ Psychopharmacol20183235736629442593
   PubMed Web of Science ®Google Scholar
• BamfordNSWightmanRMSulzerDDopamine’s effects on corticostriatal synapses during reward-based behaviorsNeuron20189749451029420932
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther200230238138912065741
   PubMed Web of Science ®Google Scholar
• TadoriYForbesRAMcQuadeRDKikuchiTCharacterization of aripiprazole partial agonist activity at human dopamine D3 receptorsEur J Pharmacol2008597273318831971
   PubMed Web of Science ®Google Scholar
• Corena-McLeodMComparative pharmacology of risperidone and paliperidoneDrugs R D20151516317425943458
   PubMed Web of Science ®Google Scholar
• BurgerGKYonkerRDCalsynRJMorseGAKlinkenbergWDA confirmatory factor analysis of the Brief Psychiatric Rating Scale in a homeless sampleInt J Methods Psychiatr Res20031219219614657975
   PubMed Web of Science ®Google Scholar
• McMillanDEGilmore-ThomasKStability of opioid craving over time as measured by visual analog scalesDrug Alcohol Depend1996402352398861402
   PubMed Web of Science ®Google Scholar